Mesoblast Finishes Enrolling 350 Patients in Phase 3 Disc Pain Cell Therapy Trial
A single intra-discal injection of stem cell therapy rexlemestrocel-L is being tested for durable pain relief in degenerative disc disease.
Summary
Mesoblast has completed treatment of 350 patients in a pivotal Phase 3 trial testing rexlemestrocel-L, a mesenchymal stromal cell therapy, for chronic low back pain caused by degenerative disc disease. The trial uses a single intra-discal injection and measures durable pain reduction at 12 months as its primary goal. Secondary endpoints include improved physical function, quality of life, and reduced reliance on opioid painkillers. The therapy holds FDA Regenerative Medicine Advanced Therapy designation, signalling its potential significance. Top-line results are expected in mid-2027. Degenerative disc disease is a major driver of disability and reduced functional capacity in aging adults, making this trial highly relevant to preserving mobility and independence as people grow older.
Detailed Summary
Chronic low back pain from degenerative disc disease is one of the leading causes of disability worldwide, robbing aging adults of mobility, independence, and quality of life. Current treatments largely manage symptoms without addressing the underlying disc degeneration, leaving a significant unmet need.
Mesoblast has now completed patient dosing in its MSB-DR004 Phase 3 randomized, placebo-controlled trial of rexlemestrocel-L — a mesenchymal stromal cell therapy delivered via a single intra-discal injection. The trial enrolled 350 patients, up from a planned 300 after strong investigator demand, suggesting meaningful clinical interest in the approach.
The primary endpoint is durable pain reduction at 12 months. Secondary endpoints include improvements in physical function, quality of life, and cessation of pain medications including opioids — a particularly important outcome given the opioid crisis and the long-term harms of chronic opioid use in older adults. The therapy carries FDA Regenerative Medicine Advanced Therapy designation, an accelerated pathway reserved for treatments targeting serious conditions with unmet needs.
This trial aims to confirm positive signals from the earlier MSB-DR003 study. If successful, rexlemestrocel-L could become the first regenerative cell therapy approved for degenerative disc disease. Top-line results are expected in mid-2027 after the last treated patient completes a full 12-month follow-up period.
From a longevity and healthspan perspective, preserving spinal function and reducing chronic pain directly supports physical performance, exercise capacity, and independence in aging populations. The potential to reduce opioid dependence adds further value. However, the trial is not yet complete, results are pending, and commercial projections of over $10 billion in U.S. revenue reflect optimistic market assumptions that should be interpreted cautiously until efficacy and safety data are published.
Key Findings
- 350 patients completed dosing in a Phase 3 trial of a single intra-discal cell therapy injection for disc-related back pain.
- Primary endpoint is durable pain reduction at 12 months; secondary endpoints include function, quality of life, and opioid cessation.
- Rexlemestrocel-L holds FDA Regenerative Medicine Advanced Therapy designation, indicating recognized unmet need.
- Top-line results are expected mid-2027, potentially making this the first approved regenerative therapy for degenerative disc disease.
- Enrollment expanded from 300 to 350 patients due to investigator demand, suggesting strong clinical interest.
Methodology
This is a news report summarizing a company press release about a Phase 3 clinical trial milestone. No peer-reviewed data have been published yet; evidence basis is the company's own statements. Source is Longevity.Technology, a credible longevity-focused outlet, but independent verification of claims is advised.
Study Limitations
All data and projections come from a company press release, not peer-reviewed publication. Trial results are pending until mid-2027 and may not confirm earlier Phase 2 signals. Commercial revenue estimates are speculative and should not influence interpretation of clinical outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: